DMPI Stock Price, News & Analysis

DelMar Pharmaceuticals, Inc. is a clinical-stage drug development company focused on creating and commercializing anti-cancer therapies for patients who have failed or become intolerant to existing treatments. Founded in 2010 and publicly traded on NASDAQ since 2013, the company has dedicated its research efforts to addressing significant unmet medical needs in oncology, particularly in aggressive and treatment-resistant cancers.

The company's lead product candidate is VAL-083, a DNA-targeting agent currently in Phase II clinical trials. VAL-083 is being evaluated for the treatment of various drug-resistant solid tumors, including glioblastoma multiforme (GBM), ovarian cancer, non-small cell lung cancer, and diffuse intrinsic pontine glioma. The compound has shown promise in targeting cancers that have developed resistance to standard chemotherapy protocols.

DelMar has established strategic collaborations to advance its clinical programs and expand its market reach. The company maintains a partnership with Guangxi Wuzhou Pharmaceutical (Group) Co. Ltd. for manufacturing and selling VAL-083 in China, and collaborates with Duke University to evaluate VAL-083 as a front-line treatment for newly diagnosed GBM patients. Additionally, DelMar has pursued corporate expansion through a merger agreement with Adgero Biopharmaceuticals Holdings, Inc., which brings a late-stage photodynamic therapy platform for cutaneous oncology indications to the combined entity.